SCNI Scinai Immunotherapeutics Ltd.
Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 1611747 · Fiscal year ends 12/31
Financial factors as of 2025-12-31 (FY2025), by fiscal year; growth vs the previous fiscal year
Growth
Margins
Returns
Leverage & solvency
Cash quality & payout
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2023Q22023-06-30 · USD | 2023Q12023-03-31 · USD | 2022Q22022-06-30 · USD | 2022Q12022-03-31 · USD | 2021Q3*2021-09-30 · ILS | 2021Q2*2021-06-30 · ILS | 2020Q4*2020-12-31 · ILS | 2020Q3*2020-09-30 · ILS |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | — | — | — | — | — | — | — | — |
| R&D expense | $1.45M | $2.00M | $1.97M | $1.16M | 2.02M | 1.90M | 7.87M | 12.58M |
| SG&A expense | $1.14M | $1.19M | $1.29M | $1.45M | 6.20M | 7.00M | 4.26M | 7.30M |
| Operating income | -$2.60M | -$3.19M | -$3.26M | -$2.62M | — | — | — | — |
| Interest expense | — | — | 3.64MILS | — | 2.80M | 3.09M | 773,000 | 288,000 |
| Net income | -$3.76M | -$3.52M | -$2.98M | -$2.48M | -9.05M | -11.99M | -14.10M | 55.31M |
| EBITDA | -$2.45M | -$3.05M | -$3.12M | -$2.48M | — | — | — | — |
| EPS (basic) | -0.00 | -0.00 | -0.00 | -0.00 | -0.02 | -0.03 | — | 0.12 |
| EPS (diluted) | -0.00 | -0.00 | -0.00 | -0.00 | -0.02 | -0.03 | — | 0.10 |
| Weighted avg. shares (diluted) | 1.35B | 1.30B | 746.90M | 744.71M | 573.21M | 573.21M | — | 538.50M |
| Balance sheet | ||||||||
| Cash & equivalents | $7.51M | $10.80M | $11.29M | $15.39M | 34.67M | 39.88M | 9.42M | 24.77M |
| Receivables | — | — | $179,000 | — | 1.43M | 2.64M | 1.20M | 2.93M |
| Current assets | $7.77M | $11.04M | $11.46M | — | 36.10M | 42.52M | 10.62M | 27.70M |
| PP&E, net | $10.80M | $10.82M | $11.21M | — | 38.61M | 38.98M | 39.61M | 39.89M |
| Total assets | $19.90M | $23.29M | $24.45M | — | 81.03M | 88.05M | 56.91M | 74.92M |
| Current liabilities | $1.89M | $2.58M | $6.72M | — | 70.27M | 69.39M | 64.19M | 11.15M |
| Total liabilities | $27.01M | $28.10M | $23.17M | — | 76.84M | 76.66M | 71.51M | 76.76M |
| Shareholders' equity | -$7.11M | -$4.81M | $3.26M | -$862,000 | 4.19M | 11.39M | -14.60M | -1.84M |
| Shares outstanding | 1.45B | 1.31B | — | — | — | — | — | — |
| Cash flow statement | ||||||||
| Operating cash flow | -$2.88M | -$3.06M | -10.41MILS | -$1.10M | -6.19M | -7.91M | -15.91M | -10.31M |
| Capital expenditure | $377,000 | $6,000 | 44,000ILS | $521,000 | 4,000 | 106,000 | 97,000 | 3.35M |
| Free cash flow | -$3.25M | -$3.06M | -10.45MILS | -$1.63M | -6.19M | -8.02M | -16.00M | -13.66M |
| Investing cash flow | -$377,000 | -$6,000 | -84,000ILS | -$521,000 | -13,000 | -107,000 | 321,000 | -3.35M |
| Financing cash flow | — | — | -468,000ILS | — | -988,000 | -317,000 | -312,000 | -140,000 |
| Depreciation & amortization | $147,000 | $138,000 | $145,000 | $134,000 | — | — | — | — |
| Stock-based compensation | $200,000 | $252,000 | 1.30MILS | $485,000 | 2.53M | 2.58M | 1.34M | 4.60M |
Free plan shows the latest 8 periods; Pro shows all 12 🔒
· This company uses different currencies across periods or line items (e.g. USD convenience translations in annual reports). Each column header shows its currency and cells in a different currency are marked; do not compare figures across currencies. Charts use only periods in the latest period's currency.
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.